The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo |
| |
Authors: | Loo Deryk Pryer Nancy Young Peter Liang Tony Coberly Suzanne King Kathleen L Kang Key Roberts Penny Tsao Mary Xu Xiaolin Potts Beverly Mather Jennie P |
| |
Affiliation: | Raven Biotechnologies Inc., 1140 Veterans Boulevard, South San Francisco, CA 94080, USA. dloo@ravenbio.com |
| |
Abstract: | RAV12 is a chimeric antibody that recognizes an N-linked carbohydrate antigen (RAAG12) strongly expressed on multiple solid organ cancers. More than 90% of tumors of colorectal, gastric, and pancreatic origin express RAAG12, and a majority of these tumors exhibit uniform RAAG12 expression. RAV12 exhibits potent cytotoxic activity in vitro against COLO 205 colon tumor cells via an oncotic cell death mechanism. RAV12-treated COLO 205 cells undergo morphologic changes consistent with oncosis, including cytoskeletal rearrangement, rapid plasma membrane swelling, and cell lysis. RAV12 inhibited the growth of RAAG12-expressing gastrointestinal tumor xenografts in athymic mice. In the case of SNU-16 tumor cells, twice weekly treatment of established s.c. tumors with 10 mg/kg RAV12 caused a approximately 70% suppression of tumor growth at the end of the study. This preclinical data has led to the initiation of a phase I/IIA clinical study of RAV12 in patients with metastatic or recurrent adenocarcinoma. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|